Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

Nature Medicine

Volumn 5, Issue 5, 1999, Pages 512-517

  Finzi, Diana ^a   Blankson, Joel ^a   Siliciano, Janet D ^a   Margolick, Joseph B ^b   Chadwick, Karen ^b   Pierson, Theodore ^a   Smith, Kendall ^c   Lisziewicz, Julianna ^d   Lori, Franco ^d   Flexner, Charles ^a   Quinn, Thomas C ^a,e   Chaisson, Richard E ^a   Rosenberg, Eric ^f   Walker, Bruce ^f   Gange, Stephen ^b   Gallant, Joel ^a   Siliciano, Robert F ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; FEMALE; HALF LIFE TIME; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT VIRUS INFECTION; MALE; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HALF-LIFE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD; VIRUS LATENCY; VIRUS REPLICATION;

EID: 0032953920     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/8394     Document Type: Article

References (41)

1. Harper, M.E., Marselle, L.M., Gallo, R.C., & Wong-Staal F. Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization. Proc. Natl. Acad. Sci. USA 83, 772-776 (1986).
2. Coombs, R.W. et al. Plasma viremia in human immunodeficiency virus infection. N. Engl. J. Med. 321, 626-1631 (1989).
3. Ho, D.D., Moudgil, T. & Alam, M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N. Engl. J. Med. 321, 1621-1625 (1989).
4. Psallidopoulus, M.C. et al. Integrated proviral human immunodeficiency virus type 1 is present in CD4+ peripheral blood lymphocytes in healthy seropositive individuals. J. Virol. 63, 4626-4631 (1989).
5. Schnittman, S.M. et al. The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science 245, 305-308 (1989).
6. Daar, E.S., Moudgil, T., Meyer, R.D. & Ho, D.D. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N. Engl. J. Med. 324, 961-964 (1991).
7. Pantaleo, G. et al. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 88, 9838-9842 (1991).
8. Pantaleo, G. et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362, 355-358 (1993).
9. Piatak, M.Jr. et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259, 1749-1754 (1993).
10. Mellors, J.W., Rinaldo, Jr., C.W., Gupta, P., White, R.M., Todd, J.A. & Kingsley, L.A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272, 1167-1170 (1996).
11. Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122 (1995).
12. Ho, D.D., Neumann, A.U., Perelson, A.S., Chen, W., Leonard, J.M. & Markowitz, M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126 (1995).
13. Perelson, A.S, Neumann, A.U., Markowitz, M., Leonard, J.M. & Ho, D.D. HIV-1 dynamics in vivo, virion clearance rate, infected cell life-span, viral generation time. Science 271, 1582-1586 (1996).
14. Perelson, A.S. et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387, 188-191 (1997).
15. Gulick, R.M. et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337, 734-739 (1997).
16. Hammer, S.M. et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 337, 725-733 (1997).
17. Harris, M. et al. Correlation of virus load in plasma and lymph node tissue in human immunodeficiency virus infection. J. Infect. Dis. 176, 1388-1392 (1997).
18. Nabel, G. & Baltimore, D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326, 711-713 (1987).
19. Folks, T.M. et al. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc. Natl. Acad. Sci. USA 86, 2365-2368 (1989).
20. Pomerantz, R.J., Trono, D., Feinberg, M.B., & Baltimore D. Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression, a molecular model for latency. Cell 61, 1271-1276 (1990).
21. Garcia-Blanco, M.A. & Cullen, B.R. Molecular basis of latency in pathogenic human viruses. Science 254, 815-820 (1991).
22. Chun, T.-W. et al. Fate of HIV-1-infected T cells in vivo, Rates of transition to stable latency. Nature Med 1, 1284-1290 (1995).
23. Chun, T.-W. et al. Quantitation of latent tissue reservoirs and total body load in HIV-1 infection. Nature 387, 183-188 (1997).
24. Folks, T. et al. Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV. J. Immunol. 136, 4049-4053 (1986).
25. Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300 (1997).
26. Chun, T.W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94, 13193-13197 (1997).
27. Wong, J.K. et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc. Natl. Acad. Sci. USA 94, 12574-12579 (1997).
28. Carpenter, C.C. et al. Antiretroviral therapy for HIV infection in 1998, undated recommendation of the International AIDS Society - USA Panel. J. Am. Med. Assoc. 280, 78-86 (1998).
29. Bartlett, J.G. in Medical Management of HIV Infection (Johns Hopkins University, Baltimore, Maryland, 1998).
30. Laird, N.M. & Ware, J.H. Random effects models for longitudinal data. Biometrics 38, 963-974 (1982).
31. Palella, F.J. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338, 853-860 (1998).
32. Flexner, C. HIV-1 protease inhibitors. N. Engl. J. Med. 338, 1281-1292 (1998).
33. Mclean, A.R. & Michie, C.A. In vivo estimates of division and death rates of human T lymphocytes. X. Proc. Natl. Acad. Sci. USA 92, 3707-3711 (1995).
34. Natarajan, V. et al. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy. Lancet 353, 119-120 (1999).
35. Gunthard, H.F. et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J. Virol. 72, 2422-2428 (1998).
36. Rosenberg, E.S. et al. Vigorous HIV-1-specific CD4+ T cell responses associated with the control of viremia. Science 278, 1447-1450 (1997).
37. Jacobson, E.L., Pilaro, F., & Smith, K.A. Rational interleukin 2 therapy for HIV positive individuals, Daily low doses enhace immune fuction without toxicity. Proc. Natl. Acad. Sci. USA 93, 10405-10410 (1996).
38. Chun, T.-W. et al. Effect of interleukin-2 in diminution of a pool of latently infected, resting CD4+ T cells in HIV-1 infected patients receiving highly active antiretroviral therapy (6th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, 1999).
39. Myers, L.A., McQuay, L.J. & Hollinger, F.B. Dilution assay statistics. J. Clin. Micro. 32, 732-739 (1994).
40. Zack, J.A. et al. HIV-1 entry into quiescent primary lymphocytes, molecular analysis reveals a labile, latent viral structure. Cell 61, 213-222 (1990).
41. Bukrinsky, M.I., Stanwick, T.L., Dempsey, M.P. & Stevenson, M. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 254, 423-427 (1991).